Sandrine Da Cruz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sandrine Da Cruz has a total of 202 co-authors. Here are the top co-authors by number of shared publications:
- Don W. Cleveland
Department of Cellular and Molecular Medicine, University of California at San Diego, La Jolla, USA
9 shared publications Melissa McAlonis-Downes
Department of Cellular and Molecular Medicine, University of California at San Diego, La Jolla, USA
5 shared publicationsJonathan Artates
Department of Cellular and Molecular Medicine, University of California at San Diego, La Jolla, USA
4 shared publications- Melissa McAlonis-Downes
Ludwig Institute for Cancer Research, University of California at San Diego, La Jolla, USA
4 shared publications - Christopher E. Shaw
UK Dementia Research Institute Centre at King’s College London, School of Neuroscience, King’s College London, London, UK
3 shared publications Clotilde Lagier-Tourenne
3 shared publications
Latest Publications
- Open Access
SubCellSpace: Automated characterization of subcellular mRNA localization patterns in spatial transcriptomics
The localized translation of transcripts is a universal phenomenon across biological domains. Many examples of subcellular RNA localization and their functional importance have been described. However, these examples remain anecdotal, and a more systematic genome and cell-type-wide analysis is needed. Current spatial transcriptomic techniques can characterize hundreds to thousands of transcript species at subcellular resolutions, enabling the large-scale investigation of subcellular mRNA localization. Here we describe SubCellSpace, a computational framework to learn general representations of mRNA localization patterns. By embedding observed single-cell subcellular localization patterns (SLPs) to an interpretable latent space, SubCellSpace can detect and statistically infer the presence of SLPs, uncover colocalizing gene-pairs and characterize cellular heterogeneity for pattern-presentation. We benchmark SubCellSpace in both synthetic and real data, showing it can correctly detect previously described apical/basal polarized genes in the enterocytes of mouse small-intestine, as well as encode the enterocytes’ orientation. Additionally, we provide a tailored spatial transcriptomics validation dataset for benchmarking SLP identification based on transcripts previously described to be enriched near subcellular structures in HEK293T cells. We propose a practical and computationally-efficient classification workflow that automatically detects localized transcript species and quantifies their degree of patterning, while controlling false positive rates. Finally, we showcase SubCellSpace in both supervised and unsupervised settings, to either classify pre-determined SLPs or to explore spatial patterning without specifying pattern types a priori . Automated AI models such as SubCellSpace and their integration in spatial transcriptomics analysis workflows will help characterize previously undiscovered subcellular RNA localization phenomena, providing novel insights into post-transcriptional regulation mechanisms.
Open AccessSubCellSpace: Automated characterization of subcellular mRNA localization patterns in spatial transcriptomics
The localized translation of transcripts is a universal phenomenon across biological domains. Many examples of subcellular RNA localization and their functional importance have been described. However, these examples remain anecdotal, and a more systematic genome and cell-type-wide analysis is needed. Current spatial transcriptomic techniques can characterize hundreds to thousands of transcript species at subcellular resolutions, enabling the large-scale investigation of subcellular mRNA localization. Here we describe SubCellSpace, a computational framework to learn general representations of mRNA localization patterns. By embedding observed single-cell subcellular localization patterns (SLPs) to an interpretable latent space, SubCellSpace can detect and statistically infer the presence of SLPs, uncover colocalizing gene-pairs and characterize cellular heterogeneity for pattern-presentation. We benchmark SubCellSpace in both synthetic and real data, showing it can correctly detect previously described apical/basal polarized genes in the enterocytes of mouse small-intestine, as well as encode the enterocytes’ orientation. Additionally, we provide a tailored spatial transcriptomics validation dataset for benchmarking SLP identification based on transcripts previously described to be enriched near subcellular structures in HEK293T cells. We propose a practical and computationally-efficient classification workflow that automatically detects localized transcript species and quantifies their degree of patterning, while controlling false positive rates. Finally, we showcase SubCellSpace in both supervised and unsupervised settings, to either classify pre-determined SLPs or to explore spatial patterning without specifying pattern types a priori . Automated AI models such as SubCellSpace and their integration in spatial transcriptomics analysis workflows will help characterize previously undiscovered subcellular RNA localization phenomena, providing novel insights into post-transcriptional regulation mechanisms.
- Open Access
- 22 December 2025
- Published by Springer Nature in Nature Neuroscience
- Vol. 29 (1) , 53-66
Axonal Eif5a hypusination controls local translation and mitigates defects in FUS-ALS
Local protein synthesis is vital for neuronal function, but its dysregulation in neurodegenerative diseases remains poorly defined. Here we applied spatial transcriptomics to adult mouse motor nerve axons and cell bodies to enable subcellular mapping. Among transcripts found in mature axons, the most enriched biological process is protein translation, and localization of translation machinery was confirmed using multiplexed single-molecule spatial transcriptomics combined with immunofluorescence. Amyotrophic lateral sclerosis (ALS)-associated mutations in the RNA-binding protein fused in sarcoma (FUS), which suppress local translation, disrupt the compartment-specific RNA signatures, including components of the translation machinery. In particular, eukaryotic initiation factor 5a (Eif5a), a translation factor involved in elongation and termination, is found to be locally impaired in mutant FUS axons with reduced levels of its active hypusinated form. Axon-specific treatment with polyamine spermidine restores Eif5a hypusination and ameliorates mutant FUS-dependent neuronal defects, including suppression of local protein synthesis. Finally, in vivo spermidine treatment reduces ALS-related toxicity in mutant FUS and TDP-43 Drosophila models, which may have implications for therapy development.
- 22 December 2025
- Published by Springer Nature in Nature Neuroscience
- Vol. 29 (1) , 53-66
Open AccessAxonal Eif5a hypusination controls local translation and mitigates defects in FUS-ALS
Local protein synthesis is vital for neuronal function, but its dysregulation in neurodegenerative diseases remains poorly defined. Here we applied spatial transcriptomics to adult mouse motor nerve axons and cell bodies to enable subcellular mapping. Among transcripts found in mature axons, the most enriched biological process is protein translation, and localization of translation machinery was confirmed using multiplexed single-molecule spatial transcriptomics combined with immunofluorescence. Amyotrophic lateral sclerosis (ALS)-associated mutations in the RNA-binding protein fused in sarcoma (FUS), which suppress local translation, disrupt the compartment-specific RNA signatures, including components of the translation machinery. In particular, eukaryotic initiation factor 5a (Eif5a), a translation factor involved in elongation and termination, is found to be locally impaired in mutant FUS axons with reduced levels of its active hypusinated form. Axon-specific treatment with polyamine spermidine restores Eif5a hypusination and ameliorates mutant FUS-dependent neuronal defects, including suppression of local protein synthesis. Finally, in vivo spermidine treatment reduces ALS-related toxicity in mutant FUS and TDP-43 Drosophila models, which may have implications for therapy development.
- Open Access
Motor System Oligodendroglia Atlas Reveals Activation States Associated with Region-Specific Vulnerability in ALS
Oligodendrocytes, the second most abundant cell type in the motor cortex and the most abundant in the spinal cord, are increasingly recognized as active contributors to neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). Yet their diversity and disease relevance in the central nervous system remain incompletely defined. Here, we generate a comprehensive single-nucleus transcriptomic atlas of 176 samples, integrating 2 in-house and 16 publicly available datasets. It encompasses more than 1,000,000 cells (350,000 oligodendrocytes and oligodendrocyte precursors) from the human motor cortex and spinal cord in non-neurological controls and ALS patients. We identify a previously unrecognized oligodendrocyte subpopulation, marked by PPEF1, and uncover regional differences, with distinct OPALIN+ and RBFOX1+ oligodendrocyte proportions between cortex and spinal cord. Importantly, we demonstrate that 'disease-associated oligodendrocytes' (DAOs) represent a distinct activation state, rather than a distinct subpopulation. In ALS, spinal cord oligodendrocytes selectively shift toward reactive states, characterized by JUND-enriched regulon activity, heightened metabolic demand, increased intercellular signaling, and activation of cell-death pathways. Finally, we identify LRP2 as a novel transcriptional oligodendrocyte marker and find LRP2 and MBP proteins to be elevated in ALS cerebrospinal fluid (CSF), offering a potential biomarker of oligodendrocyte dysfunction. Our study provides a systems-level framework to interpret oligodendrocyte and OPC changes in ALS, linking cell state shifts to molecular alterations that can guide biomarker and therapeutic strategies.
Open AccessMotor System Oligodendroglia Atlas Reveals Activation States Associated with Region-Specific Vulnerability in ALS
Oligodendrocytes, the second most abundant cell type in the motor cortex and the most abundant in the spinal cord, are increasingly recognized as active contributors to neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). Yet their diversity and disease relevance in the central nervous system remain incompletely defined. Here, we generate a comprehensive single-nucleus transcriptomic atlas of 176 samples, integrating 2 in-house and 16 publicly available datasets. It encompasses more than 1,000,000 cells (350,000 oligodendrocytes and oligodendrocyte precursors) from the human motor cortex and spinal cord in non-neurological controls and ALS patients. We identify a previously unrecognized oligodendrocyte subpopulation, marked by PPEF1, and uncover regional differences, with distinct OPALIN+ and RBFOX1+ oligodendrocyte proportions between cortex and spinal cord. Importantly, we demonstrate that 'disease-associated oligodendrocytes' (DAOs) represent a distinct activation state, rather than a distinct subpopulation. In ALS, spinal cord oligodendrocytes selectively shift toward reactive states, characterized by JUND-enriched regulon activity, heightened metabolic demand, increased intercellular signaling, and activation of cell-death pathways. Finally, we identify LRP2 as a novel transcriptional oligodendrocyte marker and find LRP2 and MBP proteins to be elevated in ALS cerebrospinal fluid (CSF), offering a potential biomarker of oligodendrocyte dysfunction. Our study provides a systems-level framework to interpret oligodendrocyte and OPC changes in ALS, linking cell state shifts to molecular alterations that can guide biomarker and therapeutic strategies.
- Open Access
- 6 November 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (1)
Early brain-wide disruption of sleep microarchitecture in amyotrophic lateral sclerosis
BACKGROUND: Amyotrophic lateral sclerosis (ALS), the major adult-onset motor neuron disease, is preceded by an early period unrelated to motor symptoms, including altered sleep, with increased wakefulness and decreased deep nonrapid eye movement (NREM). Whether these alterations in sleep macroarchitecture are associated with — or even precede — abnormalities in sleep-related EEG features remains unknown. METHODS: Here, we characterize sleep microarchitecture using polysomnography for patients with ALS ( n = 33) and controls ( n = 32) as well as for asymptomatic carriers of superoxide dismutase 1 ( SOD1 ) or C9ORF72 mutations ( n = 57) and noncarrier controls ( n = 30). Patients and controls with factors that could confound sleep structure, including respiratory insufficiency, were prospectively excluded. The results were complemented in 3 ALS mouse models ( Sod1 G86R , Fus ΔNLS/+ , and TDP-43 Q331K ). RESULTS: We observed a brain-wide reduction in the density of sleep spindles, slow oscillations, and K-complexes in patients with early-stage ALS and in presymptomatic gene carriers. These defects in sleep spindles and slow oscillations correlated with cognitive performance in both cohorts, particularly with scores on memory, verbal fluency, and language function. Alterations in sleep microarchitecture were replicated in 3 mouse models, and decreases in sleep spindles were rescued following intracerebroventricular supplementation of melanin-concentrating hormone (MCH) or by oral administration of a dual orexin receptor antagonist. CONCLUSION: Sleep microarchitecture was associated with cognitive deficits and causally linked to aberrant MCH and orexin signaling in ALS. FUNDING: Agence Nationale de la Recherche (ANR); Fondation Thierry Latran; Association Francaise de Recherche sur la sclérose latérale amyotrophique; Association Française contre les myopathies; TargetALS; and Joint Program on Neurodegenerative Diseases Research (JPND).
- 6 November 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (1)
Open AccessEarly brain-wide disruption of sleep microarchitecture in amyotrophic lateral sclerosis
BACKGROUND: Amyotrophic lateral sclerosis (ALS), the major adult-onset motor neuron disease, is preceded by an early period unrelated to motor symptoms, including altered sleep, with increased wakefulness and decreased deep nonrapid eye movement (NREM). Whether these alterations in sleep macroarchitecture are associated with — or even precede — abnormalities in sleep-related EEG features remains unknown. METHODS: Here, we characterize sleep microarchitecture using polysomnography for patients with ALS ( n = 33) and controls ( n = 32) as well as for asymptomatic carriers of superoxide dismutase 1 ( SOD1 ) or C9ORF72 mutations ( n = 57) and noncarrier controls ( n = 30). Patients and controls with factors that could confound sleep structure, including respiratory insufficiency, were prospectively excluded. The results were complemented in 3 ALS mouse models ( Sod1 G86R , Fus ΔNLS/+ , and TDP-43 Q331K ). RESULTS: We observed a brain-wide reduction in the density of sleep spindles, slow oscillations, and K-complexes in patients with early-stage ALS and in presymptomatic gene carriers. These defects in sleep spindles and slow oscillations correlated with cognitive performance in both cohorts, particularly with scores on memory, verbal fluency, and language function. Alterations in sleep microarchitecture were replicated in 3 mouse models, and decreases in sleep spindles were rescued following intracerebroventricular supplementation of melanin-concentrating hormone (MCH) or by oral administration of a dual orexin receptor antagonist. CONCLUSION: Sleep microarchitecture was associated with cognitive deficits and causally linked to aberrant MCH and orexin signaling in ALS. FUNDING: Agence Nationale de la Recherche (ANR); Fondation Thierry Latran; Association Francaise de Recherche sur la sclérose latérale amyotrophique; Association Française contre les myopathies; TargetALS; and Joint Program on Neurodegenerative Diseases Research (JPND).
- Top Cited PapersOpen Access
- 4 June 2025
- Published by Springer Nature in Molecular Neurodegeneration
- Vol. 20 (1) , 1-35
RNA-binding proteins in ALS and FTD: from pathogenic mechanisms to therapeutic insights
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are devastating neurodegenerative disorders with overlapping clinical, genetic and pathological features. A large body of evidence highlights the critical role of RNA-binding proteins (RBPs) – in particular TAR DNA-binding protein 43 (TDP-43) and Fused in sarcoma (FUS) – in the pathogenesis of these diseases. These RBPs normally regulate various key aspects of RNA metabolism in the nervous system (by assembling into transient biomolecular condensates), but undergo cytoplasmic mislocalization and pathological aggregation in ALS and FTD. Furthermore, emerging evidence suggests that RBP-containing aggregates may propagate through the nervous system in a prion-like manner, driving the progression of these neurodegenerative diseases. In this review, we summarize the genetic and neuropathological findings that establish RBP dysfunction as a central theme in ALS and FTD, and discuss the role of disease-associated RBPs in health and disease. Furthermore, we review emerging evidence regarding the prion-like properties of RBP pathology, and explore the downstream mechanisms that drive neurodegeneration. By unraveling the complex role of RBPs in ALS and FTD, we ultimately aim to provide insights into potential avenues for therapeutic intervention in these incurable disorders.
- 4 June 2025
- Published by Springer Nature in Molecular Neurodegeneration
- Vol. 20 (1) , 1-35
Top Cited PapersOpen AccessRNA-binding proteins in ALS and FTD: from pathogenic mechanisms to therapeutic insights
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are devastating neurodegenerative disorders with overlapping clinical, genetic and pathological features. A large body of evidence highlights the critical role of RNA-binding proteins (RBPs) – in particular TAR DNA-binding protein 43 (TDP-43) and Fused in sarcoma (FUS) – in the pathogenesis of these diseases. These RBPs normally regulate various key aspects of RNA metabolism in the nervous system (by assembling into transient biomolecular condensates), but undergo cytoplasmic mislocalization and pathological aggregation in ALS and FTD. Furthermore, emerging evidence suggests that RBP-containing aggregates may propagate through the nervous system in a prion-like manner, driving the progression of these neurodegenerative diseases. In this review, we summarize the genetic and neuropathological findings that establish RBP dysfunction as a central theme in ALS and FTD, and discuss the role of disease-associated RBPs in health and disease. Furthermore, we review emerging evidence regarding the prion-like properties of RBP pathology, and explore the downstream mechanisms that drive neurodegeneration. By unraveling the complex role of RBPs in ALS and FTD, we ultimately aim to provide insights into potential avenues for therapeutic intervention in these incurable disorders.
- Top Cited PapersOpen Access
TDP-43 seeding induces cytoplasmic aggregation heterogeneity and nuclear loss of function of TDP-43
Top Cited PapersOpen AccessTDP-43 seeding induces cytoplasmic aggregation heterogeneity and nuclear loss of function of TDP-43
- Top Cited Papers
- 29 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (783) , eadm7580
Early-onset sleep alterations found in patients with amyotrophic lateral sclerosis are ameliorated by orexin antagonist in mouse models
Sleep alterations have been described in several neurodegenerative diseases yet are currently poorly characterized in amyotrophic lateral sclerosis (ALS). This study investigates sleep macroarchitecture and related hypothalamic signaling disruptions in ALS. Using polysomnography, we found that both patients with ALS as well as asymptomatic C9ORF72 and SOD1 mutation carriers exhibited increased wakefulness and reduced non–rapid eye movement sleep. Increased wakefulness correlated with diminished cognitive performance in both clinical cohorts. Similar changes in sleep macroarchitecture were observed in three ALS mouse models ( Sod1 G86R , Fus Δ NLS/+ , and TDP43 Q331K ). A single oral administration of a dual-orexin receptor antagonist or intracerebroventricular delivery of melanin-concentrating hormone (MCH) through an osmotic pump over 15 days partially normalized sleep patterns in mouse models. MCH treatment did not extend the survival of Sod1 G86R mice but did decrease the loss of lumbar motor neurons. These findings suggest MCH and orexin signaling as potential targets to treat sleep alterations that arise in early stages of the disease.
- 29 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (783) , eadm7580
Top Cited PapersEarly-onset sleep alterations found in patients with amyotrophic lateral sclerosis are ameliorated by orexin antagonist in mouse models
Sleep alterations have been described in several neurodegenerative diseases yet are currently poorly characterized in amyotrophic lateral sclerosis (ALS). This study investigates sleep macroarchitecture and related hypothalamic signaling disruptions in ALS. Using polysomnography, we found that both patients with ALS as well as asymptomatic C9ORF72 and SOD1 mutation carriers exhibited increased wakefulness and reduced non–rapid eye movement sleep. Increased wakefulness correlated with diminished cognitive performance in both clinical cohorts. Similar changes in sleep macroarchitecture were observed in three ALS mouse models ( Sod1 G86R , Fus Δ NLS/+ , and TDP43 Q331K ). A single oral administration of a dual-orexin receptor antagonist or intracerebroventricular delivery of melanin-concentrating hormone (MCH) through an osmotic pump over 15 days partially normalized sleep patterns in mouse models. MCH treatment did not extend the survival of Sod1 G86R mice but did decrease the loss of lumbar motor neurons. These findings suggest MCH and orexin signaling as potential targets to treat sleep alterations that arise in early stages of the disease.
- Open Access
- 11 June 2024
- Published by Springer Nature in Molecular Neurodegeneration
- Vol. 19 (1) , 1-15
Frontotemporal dementia-like disease progression elicited by seeded aggregation and spread of FUS
RNA binding proteins have emerged as central players in the mechanisms of many neurodegenerative diseases. In particular, a proteinopathy of fused in sarcoma (FUS) is present in some instances of familial Amyotrophic lateral sclerosis (ALS) and about 10% of sporadic Frontotemporal lobar degeneration (FTLD). Here we establish that focal injection of sonicated human FUS fibrils into brains of mice in which ALS-linked mutant or wild-type human FUS replaces endogenous mouse FUS is sufficient to induce focal cytoplasmic mislocalization and aggregation of mutant and wild-type FUS which with time spreads to distal regions of the brain. Human FUS fibril-induced FUS aggregation in the mouse brain of humanized FUS mice is accelerated by an ALS-causing FUS mutant relative to wild-type human FUS. Injection of sonicated human FUS fibrils does not induce FUS aggregation and subsequent spreading after injection into naïve mouse brains containing only mouse FUS, indicating a species barrier to human FUS aggregation and its prion-like spread. Fibril-induced human FUS aggregates recapitulate pathological features of FTLD including increased detergent insolubility of FUS and TAF15 and amyloid-like, cytoplasmic deposits of FUS that accumulate ubiquitin and p62, but not TDP-43. Finally, injection of sonicated FUS fibrils is shown to exacerbate age-dependent cognitive and behavioral deficits from mutant human FUS expression. Thus, focal seeded aggregation of FUS and further propagation through prion-like spread elicits FUS-proteinopathy and FTLD-like disease progression.
- 11 June 2024
- Published by Springer Nature in Molecular Neurodegeneration
- Vol. 19 (1) , 1-15
Open AccessFrontotemporal dementia-like disease progression elicited by seeded aggregation and spread of FUS
RNA binding proteins have emerged as central players in the mechanisms of many neurodegenerative diseases. In particular, a proteinopathy of fused in sarcoma (FUS) is present in some instances of familial Amyotrophic lateral sclerosis (ALS) and about 10% of sporadic Frontotemporal lobar degeneration (FTLD). Here we establish that focal injection of sonicated human FUS fibrils into brains of mice in which ALS-linked mutant or wild-type human FUS replaces endogenous mouse FUS is sufficient to induce focal cytoplasmic mislocalization and aggregation of mutant and wild-type FUS which with time spreads to distal regions of the brain. Human FUS fibril-induced FUS aggregation in the mouse brain of humanized FUS mice is accelerated by an ALS-causing FUS mutant relative to wild-type human FUS. Injection of sonicated human FUS fibrils does not induce FUS aggregation and subsequent spreading after injection into naïve mouse brains containing only mouse FUS, indicating a species barrier to human FUS aggregation and its prion-like spread. Fibril-induced human FUS aggregates recapitulate pathological features of FTLD including increased detergent insolubility of FUS and TAF15 and amyloid-like, cytoplasmic deposits of FUS that accumulate ubiquitin and p62, but not TDP-43. Finally, injection of sonicated FUS fibrils is shown to exacerbate age-dependent cognitive and behavioral deficits from mutant human FUS expression. Thus, focal seeded aggregation of FUS and further propagation through prion-like spread elicits FUS-proteinopathy and FTLD-like disease progression.
- Open Access
Frontotemporal dementia-like disease progression elicited by seeded aggregation and spread of FUS
RNA binding proteins have emerged as central players in the mechanisms of many neurodegenerative diseases. In particular, a proteinopathy of fu sed in s arcoma (FUS) is present in some instances of familial Amyotrophic lateral sclerosis (ALS) and about 10% of sporadic FTLD. Here we establish that focal injection of sonicated human FUS fibrils into brains of mice in which ALS-linked mutant or wild-type human FUS replaces endogenous mouse FUS is sufficient to induce focal cytoplasmic mislocalization and aggregation of mutant and wild-type FUS which with time spreads to distal regions of the brain. Human FUS fibril-induced FUS aggregation in the mouse brain of humanized FUS mice is accelerated by an ALS-causing FUS mutant relative to wild-type human FUS. Injection of sonicated human FUS fibrils does not induce FUS aggregation and subsequent spreading after injection into naïve mouse brains containing only mouse FUS, indicating a species barrier to human FUS aggregation and its prion-like spread. Fibril-induced human FUS aggregates recapitulate pathological features of FTLD including increased detergent insolubility of FUS and TAF15 and amyloid-like, cytoplasmic deposits of FUS that accumulate ubiquitin and p62, but not TDP-43. Finally, injection of sonicated FUS fibrils is shown to exacerbate age-dependent cognitive and behavioral deficits from mutant human FUS expression. Thus, focal seeded aggregation of FUS and further propagation through prion-like spread elicits FUS-proteinopathy and FTLD-like disease progression.
Open AccessFrontotemporal dementia-like disease progression elicited by seeded aggregation and spread of FUS
RNA binding proteins have emerged as central players in the mechanisms of many neurodegenerative diseases. In particular, a proteinopathy of fu sed in s arcoma (FUS) is present in some instances of familial Amyotrophic lateral sclerosis (ALS) and about 10% of sporadic FTLD. Here we establish that focal injection of sonicated human FUS fibrils into brains of mice in which ALS-linked mutant or wild-type human FUS replaces endogenous mouse FUS is sufficient to induce focal cytoplasmic mislocalization and aggregation of mutant and wild-type FUS which with time spreads to distal regions of the brain. Human FUS fibril-induced FUS aggregation in the mouse brain of humanized FUS mice is accelerated by an ALS-causing FUS mutant relative to wild-type human FUS. Injection of sonicated human FUS fibrils does not induce FUS aggregation and subsequent spreading after injection into naïve mouse brains containing only mouse FUS, indicating a species barrier to human FUS aggregation and its prion-like spread. Fibril-induced human FUS aggregates recapitulate pathological features of FTLD including increased detergent insolubility of FUS and TAF15 and amyloid-like, cytoplasmic deposits of FUS that accumulate ubiquitin and p62, but not TDP-43. Finally, injection of sonicated FUS fibrils is shown to exacerbate age-dependent cognitive and behavioral deficits from mutant human FUS expression. Thus, focal seeded aggregation of FUS and further propagation through prion-like spread elicits FUS-proteinopathy and FTLD-like disease progression.